Related Experiment Video
Updated: Feb 1, 2026
Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
Published on: July 12, 2024
Renal Replacement Therapy in Patients with Heart and Kidney Failure
Insights
Renal Replacement Therapy, including ultrafiltration and peritoneal dialysis, effectively manages fluid overload in chronic heart failure patients with chronic kidney disease, reducing hospital readmissions and improving quality of life.
Area of Science:
- Nephrology
- Cardiology
- Internal Medicine
Background:
- High incidence of chronic kidney disease (CKD) in chronic heart failure (CHF) patients due to shared risk factors like hypertension and diabetes.
- Cardiac dysfunction leads to renal hypoperfusion, fluid overload, and diuretic resistance, complicating management.
- Renal Replacement Therapy (RRT) is crucial for fluid overload refractory to conservative measures.
Purpose of the Study:
- To evaluate the efficacy of ultrafiltration (UF) and peritoneal dialysis (PD) in managing fluid overload in CHF patients with CKD.
- To compare the benefits of PD versus intermittent UF in this patient population.
Main Methods:
- Systematic review of randomized controlled trials comparing UF with IV furosemide for decompensated heart failure.
- Analysis of studies on PD for volume-overloaded patients with refractory heart failure.
Main Results:
- UF demonstrated benefits in total body weight loss and reduced heart failure readmissions compared to IV furosemide.
- PD achieved efficient ultrafiltration and sodium extraction, decreasing hospitalizations, body weight, and improving LVEF.
- PD offers continuous ultrafiltration with less risk of hypotension and better preservation of residual kidney function compared to intermittent UF.
Conclusions:
- Both UF and PD lead to significant weight loss, reduced hospital readmissions, and improved quality of life in CHF patients with CKD.
- PD provides superior preservation of residual kidney function and can be administered at home, offering a significant advantage.
Abstract:
The incidence of chronic kidney disease (CKD) in patients with chronic heart failure (CHF) is high as CKD and CHF share underlying risk factors such as arterial hypertension, diabetes mellitus and atherosclerosis. Cardiac failure leads to renal hypoperfusion and dysfunction and then fluid overload and need for aggressive diuretic therapy. However, development of diuretic resistance represents a significant problem in the management of these patients. The role of Renal Replacement Therapy (RRT) is important for patients who do not response to conservative management of fluid overload facilitating the failing heart to restore function. According to the guidelines, venovenous isolated Ultrafiltration (UF) is indicated for patients with refractory congestion not responding to medical therapy with loop diuretics and infusion of dopamine. A systematic review of randomized controlled trials on the effect of UF vs. IV furosemide for decompensated heart failure showed a benefit of UF on total body weight loss and on readmissions due to heart failure in patients with decompensated heart failure and CKD. Peritoneal dialysis (PD) can provide efficient ultrafiltration and sodium extraction in volume overloaded patients followed by decline of hospitalization days, decrease of body weight and improvement of LVEF in patients with refractory heart failure. The continuous draw of ultrafiltrate is followed by a lesser risk of abrupt hypotension and better preservation of the residual kidney function. This represents a significant advantage of PD over intermittent UF by dialysis. In conclusion, application of UF by dialysis and PD is followed by significant total body weight loss, reduced need for hospital readmissions and better quality of life. PD has a higher probability of preservation of residual kidney function and can be used by patients at home.
